Skip to main content

Market Overview

Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade

Share:
Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade

Specialty biopharma Emergent Biosolutions Inc (NYSE: EBS) has seen its stock rise more than 40 percent over the past two years, and investors shouldn't expect to see such outsized returns going forward, according to Wells Fargo. 

The Analyst

Wells Fargo's David Maris downgraded Emergent BioSolutions from Outperform to Market Perform with a new $56 price target.

The Thesis

Investors who hold shares of Emergent BioSolutions should maintain their position, as the company continues to execute well and is backed by a management team with a reputation of overdelivering on promises, Maris said in the downgrade note. (See the analyst's track record here.) 

Emergent BioSolutions is unlikely to see an impact from potential drug pricing pressures, as its products are not standard prescription products and include treatment for chemical and biological threats, the analyst said. 

Despite the company's solid performance over the year, including a dramatic expansion and diversification of its business, the stock's valuation takes precedence, Maris said. The analyst said he's prepared to reassess Wells Fargo's new neutral position if it's warranted by Emergent BioSolutions' earnings or business development activity.  

Price Action

Shares of Emergent BioSolutions were trading lower by 3.67 percent near the end of Wednesday's trading session. 

Related Links:

Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger

Mid-Morning Market Update: Markets Open Lower; Twitter Beats Q1 Expectations

Latest Ratings for EBS

DateFirmActionFromTo
Apr 2021BenchmarkInitiates Coverage OnBuy
Feb 2021Chardan CapitalUpgradesNeutralBuy
Feb 2021Chardan CapitalDowngradesBuyNeutral

View More Analyst Ratings for EBS
View the Latest Analyst Ratings

 

Related Articles (EBS)

View Comments and Join the Discussion!

Posted-In: Biological Weapons BiopharmaceuticalAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com